ESAT-6联合MMP-14检测在HIV并肺结核患者病情评估中价值

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (624 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the value of early secretion of targeted antigen (ESAT-6) and matrix metalloproteinase 14 (MMP-14) in the evaluation of the severity of human immunodeficiency virus (HIV) patients with tuberculosis. Methods A retrospective analysis was made on 42 cases of HIV complicated with tuberculosis infection(group A), 50 cases of tuberculosis infection (group B) and 21 people of health examination (group C) in outpatient clinic from July 2018 to July 2019 in Kunming Third People′s Hospital. Fasting venous blood was taken to detect ESAT-6, MMP-14 and immune function. Results The expression of ESAT-6 in the three groups were compared, and the difference were statistically significant (P ＜ 0.05), while there was no expression in group C. Comparison of the levels of MMP-14, CD4+T, CD8+T and CD3+T cells in the three groups showed statistically significant differences (P ＜ 0.05). Among them, the MMP-14 of patients in group A and B were higher than those in group C, while group A was higher than that in group B, and the differences were statistically significant (P ＜ 0.05); the levels of CD4+T, CD8+T and CD3+T cells in group A and B were lower than those in group C, while group A was lower than that in group B, and the differences were statistically significant (P ＜ 0.05). ESAT-6 was negatively correlated with the expression of CD4+ T and CD8+ T (r = -0.34, -0.48, P ＜ 0.05). The expression of MMP-14 was negatively correlated with the expression of CD4+ T, CD8+ T, and CD3+ T (r = -0.32, -0.33, -0.54, P ＜ 0.05). MMP-14 was positively correlated with the severity of the disease (r = 0.78, P = 0.00). Conclusion The expression of ESAT-6 and MMP-14 are increased in severely ill patients with HIV and tuberculosis, and MMP-14 is significantly increased in severely ill patients. Both are closely related to disease progression, and the prognosis of these patients can be further evaluated.

Key words： Human immunodeficiency virus with tuberculosis Tuberculosis Early secretary antigentic target 6kDa protein Matrix metalloproteinase 14

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Nihong1 XIA Jiawei2 LIU Honglu1 LIU Jun3▲

Cite this article:

LU Nihong1 XIA Jiawei2 LIU Honglu1 LIU Jun3▲. Value of ESAT-6 combined with MMP-14 in the evaluation of HIV patients with tuberculosis[J]. 中国医药导报, 2020, 17(23): 115-118.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I23/115

[1] Ding P，Li X，Jia Z，et al. Muhidrug-resistant tuberculosis（MDR-TB）disease burden in China：a systematic review and spatiotemporal analysis [J]. BMC Infect Dis，2017，17（1）：57.
[2] Chanda-Kapata P，Kapata N，Klinkenberg E，et al. The prevalence of HIV among adults with pulmonary TB at a population level in Zambia [J]. BMC Infect Dis，2017，17（1）：236.
[3] World Health Organization. Global tuberculosis report 2018 [M]. Geneva：World Health Organization，2018.
[4] Wang X，Wu Y，Wang M，et al. The sensitivity of T-SPOT.TB assay in diagnosis of pediatric tuberculosis [J]. Fetal Pediatr Pathol，2014，33（2）：123-125.
[5] 国家技术监督局.HIV/AIDS诊断标准及处理原则[J].中国性病艾滋病防治，1998，4（2）：85-87.
[6] 高孟秋.《WS288-2017肺结核诊断》新标准中关于临床诊断患者判定的解析[J].中国防痨杂志，2018，40（3）：243-246.
[7] Hall EW，Morris SB，Moore BK，et al. Treatment Outcomes of Children with HIV Infection and Drug-Resistant TB in Three Provinces in South Africa，2005-2008 [J]. Pediatr Infect Dis J，2017，36（12）：e322-e327.
[8] Uplekar S，Heym B，Friocourt V，et al. Comparative genomics of Esx genes from clinical isolates of Mycobacterium tubeculosis provides evidence for gene conversion and epitope variation [J]. Infect Immun，2011，79（10）：4042-4049.
[9] Scherrer S，Landolt P，Friedel U，et al. Distribution and expression of esat-6 and cfp-10 in non-tuberculous mycobacteria isolated from lymph nodes of slaughtered cattle in Switzerland [J]. J Vet Diagn Invest，2019，31（2）：217-221.
[10] 商勇，陆燕春，解承鑫，等.不同肺结核类型患者细胞免疫功能相关性研究[J].临床肺科杂志，2017，22（7）：1176-1179.
[11] Zhang L，Cheng X，Bian S，et al. Utility of Th1-cell immune responses for distinguishing active tuberculosis from non-active tuberculosis：A case-control study [J]. PLoS One，2017，12（5）：e0177850.
[12] Moguche AO，Musvosvi M，Penn-Nicholson A，et al. Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis [J]. Cell Host Microbe，2017， 21（6）：695-706.
[13] Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases [J]. Vascular Pharmacology，2012，56（5/6）：232-244.
[14] Mehana EE，Khafaga AF，El-Blehi SS. The role of matrix metalloproteinases in osteoarthritis pathogenesis：An updated review [J]. Life Sci，2019，234（1）：1167-1186.
[15] Peters F，Becker-Pauly C. Role of meprin metalloproteases in metastasis and tumor microenvironment [J]. Cancer Metastasis Rev，2019，38（3）：347-356.
[16] Harman JL，Dobnikar L，Chappell J，et al. Epigenetic Regulation of Vascular Smooth Muscle Cells by Histone H3 Lysine 9 Dimethylation Attenuates Target Gene-Induction by Inflammatory Signaling [J]. Arterioscler Thromb Vasc Biol，2019，39（11）：2289-2302.
[17] Yu T，Jiang QJ，Yan TU，et al. Experimental Research on the Prevention and Treatment of Shufeng Xuanfei，Prescriptions on the Rat Chronic Serous Glomerulonephritis [J].世界最新医学信息文摘：电子版，2012，12（2）：62-64.
[18] Tadokera R，Meintjes GA，Wilkinson KA，et al. Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome [J]. Eur J Immunol，2014，44（1）：127-136.
[19] Zaldivia MTK，Mcfadyen JD，Bock L，et al. Platelet-Derived Microvesicles in Cardiovascular Diseases [J]. Front Cardiovasc Med，2017，4：74.
[20] Aguirre A，Blazquez-Prieto J，Amado-Rodriguez L，et al. Matrix metalloproteinase-14 triggers an anti-inflammatory proteolytic cascade in endotoxemia [J]. J Mol Med （Berl），2017，95（5）：487-497.
[21] Huang W，Andras IE，Rha GB，et al. PPARalpha and PPARgamma protect against HIV-1-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling [J]. FASEB J，2011，25（11）：3979-3988.